PeptideSkincare
GLP-1 & Skin

Wegovy Face Before and After: What the Evidence Actually Shows

By · Published May 3, 2026 · Updated October 22, 2026 · 15 min read

Start with our pillar guide: How to Fix Ozempic Face: What the Evidence Supports (2026), or browse all GLP-1 & Skin articles.

No study has tested Wegovy face before and after. No trial has photographed or measured faces in people taking Wegovy (semaglutide). The closest data come from a 20-person imaging study of GLP-1 users. Midface volume fell about 7% for every 10 kg of body weight lost, mostly from the fat just under the skin. Evidence: limited.

Never stop, skip or change a GLP-1 medication for skincare reasons. Talk to your prescriber first.

If you searched "Wegovy face before and after," you've probably already seen the photos online. Each one shows a single person. None of them tells you what will happen to your face. This guide replaces our older version, which included a month-by-month facial timeline that no study supports. We've cut it. What's left is what trials, imaging studies and the current FDA label actually report. For the wider picture, see our guide to what Ozempic face is and what can be done about it.

Key takeaways

  • No Wegovy trial has photographed faces or measured facial volume. The STEP trials measured body weight.
  • Wegovy 2.4 mg produced 14.9% mean weight loss at 68 weeks in STEP 1 and 16.0% in STEP 3.
  • In a 20-person CT/MRI study, midface volume dropped about 7% per 10 kg lost, mainly from superficial fat pads (Sharma et al., 2025).
  • The June 2026 Wegovy label lists dysesthesia in 22% and hair loss in 6% of people on the 7.2 mg dose, compared with 0% and 1% on placebo.
  • Only 2 small, maker-funded topical studies have been run in GLP-1 users (Nguyen et al., 2026; Moradi et al., 2026), and neither shows a topical replaces lost volume.

What is Wegovy face?

Wegovy face is an informal name, not a medical diagnosis, for the hollower, older-looking face some people notice after losing weight on Wegovy (semaglutide 2.4 mg). It's the same change more often called "Ozempic face": rapid weight and fat loss depletes facial volume, which can leave wrinkles and sagging skin (Humphrey & Lawrence, 2023).

The only objective measurement so far is a 20-person CT/MRI study of GLP-1 users, in which midface volume fell about 7% per 10 kg of weight lost, mostly from superficial fat (Sharma et al., 2025). Evidence: early / preliminary.

Is there a clinical study of Wegovy face before and after?

No. No published trial has photographed, scanned or rated faces in people taking Wegovy, and no registered Novo Nordisk or Eli Lilly trial lists facial change as a primary endpoint.

The big Wegovy trials (STEP 1, STEP 3 and STEP UP) tracked body weight, metabolic markers and adverse events. Facial appearance wasn't one of their outcomes. On Oct 10, 2026, we searched ClinicalTrials.gov for semaglutide or tirzepatide combined with face, skin, aesthetic or filler terms. Every registered GLP-1 aesthetic trial we found tests an injectable, enrolls 48 people or fewer, and has no results yet (NCT07478198, NCT07217743, NCT07221461, NCT07419854). For what the tirzepatide data show, see our Mounjaro face guide.

That means every Wegovy face before-and-after photo you see is an anecdote. A common pattern in GLP-1 communities is people comparing their faces to strangers' photos and worrying they're "ahead" or "behind." No dataset exists to compare against.

How much weight do people lose on Wegovy?

In the STEP trials, people lost a mean 14.9% to 16.0% of their body weight on Wegovy 2.4 mg. A higher 7.2 mg dose produced 18.7% in the STEP UP trial.

Wegovy is a brand of semaglutide, a GLP-1 receptor agonist. GLP-1 receptor agonists mimic a gut hormone that reduces appetite and slows stomach emptying.

  • STEP 1 found a mean weight loss of 14.9% at 68 weeks on semaglutide 2.4 mg (Wilding et al., 2021). Evidence: well-established.
  • STEP 3 reported a mean weight loss of 16.0% (Wadden et al., 2021).
  • STEP UP was a 72-week, double-blind, phase 3b randomized controlled trial of 1,407 adults, sponsored by Novo Nordisk. It found weight loss of 18.7% on semaglutide 7.2 mg, 15.6% on 2.4 mg and 3.9% on placebo (Wharton et al., 2025). Evidence: limited to moderate (one large, sponsor-run RCT).

According to the current Wegovy label (revised June 2026), the usual maintenance dose is 2.4 mg weekly. For weight reduction, the label allows 1.7 mg or 2.4 mg, with 2.4 mg recommended. The label also allows an increase to a maximum of 7.2 mg (Wegovy HD) if 2.4 mg has been tolerated for at least 4 weeks and more weight loss is clinically indicated.

Total weight lost matters for the face because the only GLP-1 facial imaging study found volume loss tracked weight loss.

How much facial volume do people lose with Wegovy weight loss?

In the one study that measured faces objectively, people lost a median 9.0% of midface volume after losing a mean 11.0 kg. That works out to about 7% of midface volume per 10 kg of body weight.

The study was a retrospective cohort, meaning researchers looked back at existing records. It included 20 people who had CT or MRI scans of the face before and after being prescribed a GLP-1 drug (Sharma et al., 2025). Median age was 54, mean time between scans was 321 days, and the work came from Vanderbilt. Funding was not reported in the record. Evidence: early / preliminary (single small study).

Measure (Sharma 2025, n=20) Result
Median total midface volume change −9.0%
Superficial fat change −11%
Deep fat change −7%
Approximate ratio ~7% midface volume per 10 kg lost

Three details matter for anyone comparing Wegovy face before and after:

  1. The loss was mostly superficial. Superficial fat pads sit just under the skin. Deep fat pads sit closer to bone. The superficial pads shrank more.
  2. The relationship looked roughly proportional. Our old article claimed facial loss "isn't linear" and levels off. This study doesn't support that.
  3. The cohort lost 11.0 kg on average. STEP 1 participants typically lost more than that, and nobody has measured whether the 7%-per-10-kg ratio holds at larger losses.

The study authors call their paper one of the first quantitative assessments of facial change on GLP-1 drugs. The record we have doesn't break results out by individual drug.

Does Wegovy weight loss make a face look older?

Large weight loss from any cause can make people look older to observers. One study found that raters also judged post-weight-loss faces as more attractive.

The available studies come from bariatric surgery, not Wegovy:

  • In a Cleveland Clinic retrospective study, 40 blinded raters judged 7 facelift patients who had lost more than 100 lb as looking 5.1 years older than their actual age, compared with 11 controls (Couto et al., 2015). Evidence: early / preliminary.
  • In a study of photos of 14 bariatric patients, about 100 survey raters judged them older but more attractive after weight loss. Only 5 of the 14 showed a significant change in perceived age (Papoian et al., 2015). The authors declared no conflicts. Evidence: early / preliminary.
  • A systematic review of 13 studies plus 1 abstract on surgical and medical weight loss found the most volume loss in the mid-cheek, plus skin laxity (loose skin) in the central neck (Jafar et al., 2024). Evidence: limited (observational studies).

A 2025 systematic review of 23 plastic-surgery articles concluded that GLP-1 drugs cause changes "resembling advanced aging." The authors acknowledged their conclusions were "limited by study biases," and they declared no funding or conflicts (Daneshgaran et al., 2025). A 2023 narrative review noted that prescribers "seldom counsel" patients about facial changes (Humphrey et al., 2023). Evidence: expert opinion.

Our older article said people over 40 or 50 get "more pronounced laxity." None of these sources measured that directly, so we've removed the claim. For neck-specific changes, see what happens to neck skin on GLP-1 drugs.

Does Wegovy itself damage collagen in facial skin?

No human study shows that semaglutide directly damages skin collagen. The tissue data we have come from people who lost weight after bariatric surgery, and they show a mixed picture.

A recurring claim in GLP-1 communities is that the drug "eats collagen." The closest real data come from a controlled histology study (examining skin under a microscope). It compared abdominal skin from 40 post-bariatric women with 40 women who had never been obese. Collagen was depleted, but elastic fibers were not damaged and were even increased at one site (Orpheu et al., 2010). Evidence: limited.

That study looked at abdominal skin after surgical weight loss and measured each person at a single point in time. It can't tell you what happens to facial skin on Wegovy. Our old article said elastin "degrades" during weight loss, and this study contradicts that.

What skin and hair side effects are on the Wegovy label?

The June 2026 Wegovy label lists dysesthesia and hair loss as adverse reactions, and both are much more frequent at the 7.2 mg dose. Neither one is a facial-volume effect.

Dysesthesia is an abnormal, often unpleasant sensation in the skin, such as burning, tingling or pain when the skin is touched. The label groups paresthesia, hyperesthesia, burning sensation, allodynia, dysesthesia, skin burning sensation, pain of skin and sensitive skin under this heading.

Adverse reaction (Wegovy label, June 2026) Placebo 2.4 mg 7.2 mg
Dysesthesia (7.2 mg trial) 0% 6% 22%
Hair loss (7.2 mg trial) 1% 3% 6%
Nausea (7.2 mg trial) 13% 35% 39%

In the original adult weight-reduction trials of 2.4 mg, the label reports hair loss in 3% vs 1% on placebo and dysesthesia in 2% vs 1%. The label also calls hair loss "associated with weight reduction." In its pooled data, hair loss affected 3.3% of people on 2.4 mg (4% of females, 0.9% of males) vs 1% on placebo. The current label highlights now list dysesthesia among the most common adverse reactions (≥5%).

The STEP UP trial reported dysaesthesia (the British spelling) in 22.9% on 7.2 mg, 6.0% on 2.4 mg and 0.5% on placebo (Wharton et al., 2025). Novo Nordisk's own conference poster described most cases as mild, with none serious and most resolving during treatment. That poster is not peer reviewed. Dysesthesia is a sensation problem, and no evidence supports treating it as a skin-barrier problem. Our Mounjaro skin sensitivity guide covers it in more depth.

Hair loss has broader support. A 2026 meta-analysis of 9 interventional studies (7 RCTs) covering 4,114 GLP-1 users found hair loss risk was 3.25 times higher than with placebo (95% CI 1.44–7.36), with a pooled event rate of 3.9% (Cheng et al., 2026). The authors reported no competing interests. Evidence: well-established.

What FDA adverse event reports show

FAERS is the FDA Adverse Event Reporting System, a database of voluntary reports from patients and clinicians. FAERS reports show what patients and clinicians reported while on a drug. They don't show that the drug caused the event, and they can't be used to estimate how often it happens. Reports are voluntary and unverified. Report counts rise with the number of people using a drug and with media attention, and FAERS includes duplicates and has no denominator (no count of how many people took the drug).

How we got this data: we ran an openFDA query on Oct 10, 2026 (2:29 PM CT). We searched the generic name semaglutide, which covers Wegovy and Ozempic, for each MedDRA preferred term (MedDRA is the standard medical vocabulary for adverse events). Counts include reports listing semaglutide in any role.

MedDRA term (semaglutide, 73,001 total reports) Reports
Alopecia (hair loss) 850
Burning sensation 249
Pain of skin 95
Skin laxity 35
Skin wrinkling 28
Facial wasting 11

"Facial wasting" and "skin laxity" barely appear. That's because people rarely report a cosmetic change from weight loss as a drug reaction, so FAERS can't size the "Wegovy face" question either way.

Does a Wegovy face come back after stopping the drug?

Nobody has measured faces after stopping Wegovy. What we know is that most people regained a large share of their weight. The available data don't support the common claim that facial volume "comes back" with it.

The STEP 1 extension followed participants after they stopped semaglutide. By week 120, they had regained 11.6 percentage points of the weight they'd lost, roughly two-thirds of their earlier loss (Wilding et al., 2022). Evidence: limited (single extension cohort).

Our old article said "some facial volume typically returns" with regain. No study supports that, so we've removed it. A frequent question in GLP-1 communities runs the other way: people say their weight has been stable or crept up for months and their cheeks haven't filled back in. Those are anecdotes, but no data contradict them.

Can a lower maintenance dose change your Wegovy face before and after?

Nobody has tested it. No study has compared facial outcomes between Wegovy doses, so no dose has a demonstrated facial benefit.

The label allows 1.7 mg or 2.4 mg for weight reduction and up to 7.2 mg in some cases. Choosing among those is a medical decision based on your health, tolerability and treatment goals. It belongs to your prescriber. If facial changes bother you, say so at your next appointment, but don't adjust your dose for your face.

Can skincare or peptides help a Wegovy face?

Two small 2026 studies, each funded by the product's maker, have now tested topicals in GLP-1 users. In an open-label study with no control group, 29 of 33 adults completed 12 weeks of a volumizing cream (Image Skincare) and showed less wrinkle severity (20.7%) and thicker skin and subcutaneous tissue on ultrasound (20.1%) (Nguyen et al., 2026). In a double-blind split-face trial of 25 users, a Proxylane/flavonoid regimen (SkinCeuticals) improved laxity versus placebo after 4 weeks, then was paired with a focused-ultrasound treatment (Moradi et al., 2026). Neither shows that a topical replaces lost fat pads. As of Oct 10, 2026, ClinicalTrials.gov had no registered trial of a topical in GLP-1 users.

Topicals can't replace lost fat pads, and no evidence shows they slow GLP-1-related facial change. Peptides such as GHK-Cu (copper tripeptide-1) are general skincare ingredients with limited human evidence for skin quality. They are not a fix for GLP-1 changes. Our guide to peptides for loose skin after weight loss covers what they can and can't do for laxity. If you want to read that evidence on its own terms, see what the copper peptide research does and doesn't show, our barrier and hydration basics and our general skincare protocol. Oral collagen has its own evidence questions, covered in our collagen supplements guide.

Getting enough protein matters for overall health during weight loss. No study links a specific protein dose to facial skin outcomes on GLP-1 drugs, so we don't give a gram target. Ask your clinician or a registered dietitian what's right for you.

Do fillers or biostimulators work for Wegovy face?

The evidence is thin. Only one sizable study has tested injectables after GLP-1 weight loss. It had 41 participants and no control group, and it was funded by the products' manufacturer.

That study was multicenter and open-label (everyone knew what treatment they got). People received 2–3 sessions of Sculptra, a PLLA (poly-L-lactic acid) biostimulator that prompts the body to build collagen. They also received 1–2 sessions of Restylane Lyft or Contour, both HA (hyaluronic acid) gel fillers, and were followed for 9 months (Lorenc et al., 2026; NCT06351358). Galderma, which makes both products, funded the study, designed it and analyzed the data. Four co-authors are current or former Galderma employees. Participants reported better skin quality and contour, 91.4% said they would recommend the regimen, and no treatment-related adverse events were reported. Evidence: limited (manufacturer-funded, uncontrolled).

On timing, a 2026 expert consensus of 4 clinicians said these treatments "have not yet been widely studied in this population" and that timing within the weight-loss journey matters (Moradi et al., 2026). Allergan Aesthetics funded the writing support, and one author is an Allergan employee. No trial compares starting early with waiting until weight is stable. Our dermal fillers for Ozempic face guide covers options and costs.

Where the evidence stops

  • No facial data on Wegovy itself. No trial has photographed, scanned or rated faces on semaglutide.
  • One small imaging study. The 7%-per-10-kg figure comes from 20 people with mixed GLP-1 prescriptions and a mean loss of 11.0 kg.
  • No data on regain and the face. We don't know whether facial fat refills when weight returns.
  • No dose comparison. Nobody has compared facial outcomes at 1.7 mg, 2.4 mg and 7.2 mg.
  • Barely tested topicals. Only 2 small, maker-funded topical studies exist in GLP-1 users, 1 with no control group (Nguyen et al., 2026; Moradi et al., 2026).
  • Injectable trials are pending. The registered trials are small, mostly sponsored by clinics, and have no results yet.

FAQ

Has any study photographed faces before and after Wegovy? No. The STEP trials measured body weight, not faces, and no registered trial lists GLP-1 facial change as a primary endpoint. The only objective measurement comes from a 20-person CT/MRI study of GLP-1 users (Sharma et al., 2025).

How much facial volume do people lose on Wegovy? In that imaging study, median midface volume fell 9.0% after a mean weight loss of 11.0 kg, or about 7% per 10 kg (Sharma et al., 2025). Most of the loss came from superficial fat. Results in larger groups or at bigger weight losses are unknown.

Will my face come back if I stop Wegovy? Nobody has measured it. People in the STEP 1 extension regained 11.6 percentage points of their lost weight by week 120 after stopping (Wilding et al., 2022), but nobody tracked their faces. Never stop, skip or change a GLP-1 medication for skincare reasons. Talk to your prescriber first.

Does a lower Wegovy dose protect your face? No study has tested that. The Wegovy label allows 1.7 mg or 2.4 mg for weight reduction, and choosing between them is your prescriber's call based on your health. No dose has a demonstrated facial benefit.

Why does my skin hurt or burn on Wegovy? Dysesthesia (burning, tingling or skin pain) is a label-listed reaction. It affected 22% of people on 7.2 mg, 6% on 2.4 mg and 0% on placebo in the 7.2 mg trial (Wegovy label). Tell your prescriber if it happens to you.

Can peptides or other skincare prevent Wegovy face? Only 2 small, maker-funded studies have tested topicals in GLP-1 users, reporting skin-quality and laxity gains (Nguyen et al., 2026; Moradi et al., 2026). Neither shows that a topical prevents or reverses fat-pad volume loss. Peptides are general skincare ingredients with limited human evidence. They can't replace lost fat.

References

Where a full title isn't reproduced, we describe the study instead; the PubMed link has the full record.

  1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. 68-week trial; 14.9% mean weight loss. https://pubmed.ncbi.nlm.nih.gov/33567185/
  2. Wadden, et al. STEP 3 trial of semaglutide 2.4 mg. JAMA. 2021. 16.0% mean weight loss. https://pubmed.ncbi.nlm.nih.gov/33625476/
  3. Wilding JPH, et al. STEP 1 trial extension: weight regain after withdrawal of semaglutide. Diabetes Obes Metab. 2022. Follow-up to week 120. https://pubmed.ncbi.nlm.nih.gov/35441470/
  4. Wharton S, et al. STEP UP: semaglutide 7.2 mg vs 2.4 mg vs placebo. Lancet Diabetes Endocrinol. 2025. Phase 3b double-blind RCT, n=1,407, 72 weeks; Novo Nordisk sponsor. https://pubmed.ncbi.nlm.nih.gov/40961952/
  5. Novo Nordisk. WEGOVY (semaglutide) prescribing information, revised 06/2026. DailyMed SPL v19. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  6. Sharma, et al. Quantitative CT/MRI assessment of midface volume after GLP-1 prescription. Otolaryngol Head Neck Surg. 2025. Retrospective cohort, n=20; funding not reported. https://pubmed.ncbi.nlm.nih.gov/40407186/
  7. Couto, et al. Perceived age of facelift patients after massive weight loss. Aesthetic Plast Surg. 2015. Retrospective, 7 vs 11 controls, 40 blinded raters. https://pubmed.ncbi.nlm.nih.gov/26311559/
  8. Papoian, et al. Perceived age and attractiveness after bariatric weight loss. Arch Plast Surg. 2015. 14 patients, ~100 raters. https://pubmed.ncbi.nlm.nih.gov/26430627/
  9. Jafar, et al. Systematic review of facial aging after massive weight loss. Aesthet Surg J Open Forum. 2024. 13 studies + 1 abstract. https://pubmed.ncbi.nlm.nih.gov/39346804/
  10. Daneshgaran G, et al. Systematic review of GLP-1 facial changes with Google Trends analysis. Aesthet Surg J Open Forum. 2025. 23 articles; no funding or conflicts declared. https://pubmed.ncbi.nlm.nih.gov/40626110/
  11. Orpheu, et al. Skin collagen and elastic fibers after bariatric weight loss. Obes Surg. 2010. Controlled histology, 40 vs 40, abdominal skin. https://pubmed.ncbi.nlm.nih.gov/19937152/
  12. Humphrey, et al. "Ozempic face": narrative review. Facial Plast Surg. 2023. None declared. https://pubmed.ncbi.nlm.nih.gov/37541662/
  13. Cheng, et al. Meta-analysis of hair loss with GLP-1 receptor agonists. Diabetes Res Clin Pract. 2026. 9 studies (7 RCTs), n=4,114. https://pubmed.ncbi.nlm.nih.gov/42155605/
  14. Lorenc, et al. PLLA-SCA plus HA filler after GLP-1 weight loss. Aesthet Surg J. 2026. Open-label, uncontrolled, n=41, 9 months; funded by Galderma. NCT06351358. https://pubmed.ncbi.nlm.nih.gov/41243519/
  15. Moradi, et al. Expert consensus on aesthetic treatment after GLP-1 weight loss. Aesthet Surg J Open Forum. 2026. 4 clinicians; writing support funded by Allergan Aesthetics. https://pubmed.ncbi.nlm.nih.gov/41768029/
  16. openFDA drug adverse event (FAERS) API, semaglutide by MedDRA preferred term. Queried Oct 10, 2026, 2:29 PM CT. https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:%22SEMAGLUTIDE%22+AND+patient.reaction.reactionmeddrapt.exact:%22Skin%20laxity%22&limit=1
  17. ClinicalTrials.gov. NCT07478198: PLLA for facial laxity after GLP-1 therapy, n=22. https://clinicaltrials.gov/study/NCT07478198
  18. ClinicalTrials.gov. NCT07217743: Poly-L-lactic acid in GLP-1 subjects, n=20. https://clinicaltrials.gov/study/NCT07217743
  19. ClinicalTrials.gov. NCT07221461: Microdroplet HA filler in GLP-1 patients, n=24. https://clinicaltrials.gov/study/NCT07221461
  20. ClinicalTrials.gov. NCT07419854: Radiesse for facial volume after GLP-1 weight loss, n=48. https://clinicaltrials.gov/study/NCT07419854
  21. ClinicalTrials.gov. NCT06351358: Galderma PLLA-SCA plus HA study (registration for reference 14). https://clinicaltrials.gov/study/NCT06351358
  22. Nguyen N, et al. Topical volumizing cream in adults with rapid weight loss, mostly from GLP-1/GIP agonists. J Cosmet Dermatol. 2026. Open-label, no control, n=33 (29 completed), 12 weeks; funded by Image Skincare. https://pubmed.ncbi.nlm.nih.gov/41556403/
  23. Moradi A, Kim JH, et al. Flavo-Proxylane topical regimen before and after focused ultrasound in GLP-1 RA users. Dermatol Ther (Heidelb). 2026. Double-blind randomized split-face/neck, placebo-controlled, n=25, 12 weeks; funded by SkinCeuticals. https://pubmed.ncbi.nlm.nih.gov/41781778/

Disclosure: This article is for general information only. It is not medical advice. Peptide Skincare has no affiliate links in this article and received no payment from any manufacturer mentioned. Talk to your prescriber before making any change to a GLP-1 medication, and to a licensed clinician about any skin or aesthetic treatment.

For educational purposes only; not medical advice. See our disclaimer and research method.